PRODUCTS & SERVICES
CUSTOM OLIGO SYNTHESISRNA SEQUENCINGFLUORESCENT IN SITU HYBRIDIZATIONPERSONALIZED DIAGNOSTICS
MultiplexDX is the first company from the CEE region to become an honorable member of the Oslo Cancer Cluster (OCC). The cluster’s main mission is to improve cancer patients’ lives by accelerating the development of new diagnostics and treatment. It is a research-based industry cluster that brings together enterprises, organizations, academic and research institutions in the field of life sciences and converging industries like ICT. The members of OCC, which consist of over 90 companies worldwide, establish new knowledge and generate novel products and services including innovative solutions between research and business entities.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“Being a member of OCC means to get powerful support for all innovation phases from early-stage development until commercialization. The cluster’s members represent the entire oncology value chain making it an ideal environment for launching new products! We are very excited to be part of this great alliance and look forward to sharing our experience as well as developing new opportunities for our innovations!”
Also, OCC membership facilitates the participation in international conferences, helps its members to showcase their R&D activities at professional forums and meetings, establishes direct connections between cluster members and relevant international partners, and initiates meetings with public authorities in order to influence the health authorities. If so desired by a member, Oslo Cancer Cluster may involve professional advisors, undertake management of intellectual property rights, including development, filing and maintenance activities relating to patents, negotiate the agreements with development and commercial partners, prepare a scientific & business pitch deck to engage with pharma OCC members. MultiplexDX plans to expand its new business team responsible for the interactions with OCC and that will help to facilitate Multiplex9+ market entry and to secure future companion DX projects.
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and treatment. It is a national non-profit membership organization with about 90 members. The cluster’s members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field. They represent the entire oncology value chain, doing everything from exploratory research to selling therapeutics and diagnostics to global markets.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.